- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05860595
Evaluatie van de veiligheid en werkzaamheid van KL003-celinjectie bij de behandeling van transfusie-afhankelijke β-thalassemie.
This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with transfusion-dependent β-thalassemia.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Subject participation for this study will be 24 months. Subjects who enroll in this study will be asked to participate in a subsequent 13-year follow-up for gene therapy products.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Regenerative Medicine Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female age between 3-35 years
- Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years
- Documented baseline, or pretransfusion, Hb level≤7 g/dL
- Karnofsky performance status ≥70 for subjects≥16 years of age; Lansky performance status of ≥70 for subjects<16 years of age
- Eligible to undergo auto-HSCT
- Willing and able to follow the research procedures and conditions, with good compliance
- Willing to receive at least the 2 years follow-up and maintain detailed medical records, including transfusion history
- Subject and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form, and can complete all follow-up in accordance with the protocol requirements
Exclusion Criteria:
-
Subjects positive with the following etiological tests: human immunodeficiency virus(HIV-1-2), human cytomegalovirus (HCMV-DNA), EB virus (EBV-DNA), HBV (HBsAg/HBV-DNA positive), HCV antibody (HCV-Ab), Treponema pallidum antibody (TP-Ab)
-
Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator
-
Contraindication to bone marrow collection
-
Any prior or current malignancy or myeloproliferative or significant immunodeficiency disorder
-
A white blood cell (WBC) count <3×10^9/L, and/or platelet count <100×10^9/L not related to hypersplenism
-
Diagnosis of composite α thalassemia
-
Participants with severe iron overload at the time of screening: severe iron overload of the liver showed by MRI, serum ferritin ≥ 5000 ng/mL, or moderate to severe iron overload of the heart
-
Presence of unusual antibody of red blood cell antigens or tested positive for platelet antibody
-
Meet the criteria for allo-HSCT and with an identified willing donor with a full HLA match
-
Prior receipt of gene therapy or allo-HSCT
-
Immediate family member (i.e. parent or siblings) with a known Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis)
-
Diagnosis of a significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
-
History of major organ damage including:
- Liver function test suggest AST or ALT levels >3× upper limit of normal (ULN);
- Total serum bilirubin value >2.5×ULN;if combined with Gilbert syndrome, total bilirubin >3×ULN and direct bilirubin value >2.5×ULN;
- History of bridging fibrosis, cirrhosis;
- Left ventricular ejection fraction <45%;
- New York Heart Association (NYHA) class III or IV congestive heart failure;
- Severe arrhythmia requiring medical treatment;
- Uncontrolled hypertension or unstable angina pectoris;
- Myocardial infarction or bypass or stent surgery within 12 months before drug administration;
- Valvular disease with clinical significance;
- Baseline calculated eGFR<60mL/min/1.73m2;
- Pulmonary function: FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction;
- Evidence of clinically significant pulmonary hypertension requiring medical intervention.
-
Uncorrectable coagulation dysfunction or history of severe bleeding disorder
-
Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician
-
Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.)
-
Participation in another clinical study with an investigational drug within 30 days of Screening or participating in another clinical study with an investigational drug
-
Inoculated live vaccine within 6 weeks prior to screening
-
Pregnancy or breastfeeding women; Subjects or their sexual partners were unable to take medically recognized effective contraceptive measures during the 27-month study period
-
The subjects or their parents would not comply with the study procedures outlined in the protocol
-
Receipt of hydroxyurea therapy within 3 months before HSCT harvest
-
Patients considered to be ineligible for the study by the investigator for reasons other than the above
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: KL003 cell injection Drug Product
Each recruited subject will accept KL003 Transplantation. |
Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Transplantatiegerelateerde mortaliteit binnen 100 dagen en binnen 1 jaar na herinfusie van het geneesmiddel KL003
Tijdsspanne: Tot 1 jaar na transplantatie
|
Tot 1 jaar na transplantatie
|
|
|
Percentage of participants with successful lentiviral vector transduced CD34+ stem cell engraftment
Tijdsspanne: Up to 42 days post transplant
|
Successful engraftment was defined as neutrophil count [ANC] ≥0.5×10^9/L for 3 consecutive days |
Up to 42 days post transplant
|
|
Engraftment time of neutrophil
Tijdsspanne: Up to 42 days post transplant
|
The first day when neutrophils ≥ 0.5×10^9/L for 3 consecutive days |
Up to 42 days post transplant
|
|
Engraftment time of platelet
Tijdsspanne: Up to 42 days post transplant
|
The first day of platelet count ≥ 20.0×10^9/L for 7 consecutive days after platelet transfusion independence |
Up to 42 days post transplant
|
|
The number, frequency and severity of adverse events (AE) within 1 year after reinfusion of KL003 drug products
Tijdsspanne: Up to 24 months post transplant
|
Frequency and severity of AEs & SAEs identified according to NCI CTCAE 5.0 |
Up to 24 months post transplant
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
De duur van transfusie-onafhankelijkheid
Tijdsspanne: Tot 24 maanden na transplantatie
|
Tot 24 maanden na transplantatie
|
|
|
Veranderingen in de frequentie en het volume van bloedtransfusie
Tijdsspanne: Tot 24 maanden na transplantatie
|
Tot 24 maanden na transplantatie
|
|
|
The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months
Tijdsspanne: Up to 24 months post transplant
|
TI is defined as Hb ≥ 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 6 months |
Up to 24 months post transplant
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IIT2023021
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .